On ECHEMI
Home > Drugs > Beijing Fresenius Kabi Pharmaceutical Co., Ltd.
Beijing Fresenius Kabi Pharmaceutical Co., Ltd.
  • Founded in:

    1994-07-18
  • Country:

    China China
  • Address:

    No. 57, Huatuo Road, Daxing Biomedicine Industry Base, Zhongguancun Science Park, Daxing District, Beijing
  • Tax NO.:

    911100006000562780
  • Registered Funds:

    $20.6 million
  • Website:

  • Email:

Related Drugs
Compound α-keto acid tablets
The chemical name is: It is a compound preparation containing 1 hydroxyamino acid calcium, 4 ketoamino acid calcium and 5 amino acids. Its composition: racemic hydroxymethionine calcium 59mg, threonine 53mg, racemic ketoisoleucine calcium 67mg, ketoleucine calcium 101mg, ketophenylalanine calcium 68mg, ketovaline calcium 86mg, lysine acetate 105mg, tryptophan 23mg, histidine 38mg, tyrosine 30mg. Total calcium content/tablet 1.25mmol≈50mg Total nitrogen content/tablet 36mg.
Name Description Content CAS NO. Registered Holders
Calcium bis(2-hydroxy-4-(methylthio)butyrate)

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

59mg 4857-44-7 9
L-Threonine

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

53mg 72-19-5 13
Calcium 3-methyl-2-oxovalerate

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

67mg 66872-75-1 10
Ketoleucine calcium salt dihydrate

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

101mg 51828-95-6 10
Calcium phenylpyruvate

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

68mg 51828-93-4 10
Calcium alpha-ketovaline

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

86mg 51828-94-5 10
Lysine acetate

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

105mg 0
N-[(tert-Butoxy)carbonyl]-D-tryptophan

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

twenty threemg 0
L-Histidine

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

38mg 71-00-1 20
Boc-D-Tyr-OH

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

More

Providing essential amino acids and minimizing the intake of amino nitrogen can reduce urea synthesis and the accumulation of uremic toxic products, improve renal hyperphosphatemia and secondary hyperparathyroidism, and improve renal osteodystrophy

30mg 70642-86-3 9
Hydroxyethyl starch 130/0.4 electrolyte injection
Name Description Content CAS NO. Registered Holders
Hydroxyethyl starch 130/0.4

No specific pharmacological effects mentioned

More

No specific pharmacological effects mentioned

0
Hydroxyethyl starch 130/0.4 sodium chloride injection
Name Description Content CAS NO. Registered Holders
Hydroxyethyl starch 130/0.4

This product is a blood volume expander. Its volume expansion effect and blood dilution effect depend on the molecular weight, degree of substitution, substitution mode and drug concentration, as well as the dosage and infusion rate. After healthy volunteers infused 500ml of this product within 30 minutes, their volume expansion effect was 100% of the infusion volume of this product, and this 100% volume effect can be maintained stably for 4-6 hours. Using this product for isovolumetric blood replacement can maintain blood volume for at least 6 hours.

More

This product is a blood volume expander. Its volume expansion effect and blood dilution effect depend on the molecular weight, degree of substitution, substitution mode and drug concentration, as well as the dosage and infusion rate. After healthy volunteers infused 500ml of this product within 30 minutes, their volume expansion effect was 100% of the infusion volume of this product, and this 100% volume effect can be maintained stably for 4-6 hours. Using this product for isovolumetric blood replacement can maintain blood volume for at least 6 hours.

0
Sodium chloride

This product is a blood volume expander. Its volume expansion effect and blood dilution effect depend on the molecular weight, degree of substitution, substitution mode and drug concentration, as well as the dosage and infusion rate. After 500ml of this product was infused into healthy volunteers within 30 minutes, its volume expansion effect was 100% of the infusion volume of this product, and this 100% volume effect can be stably maintained for 4-6 hours. This product can maintain blood volume for at least 6 hours by isovolumetric blood replacement. In the subchronic toxicity test study of dogs and rats, this product was intravenously infused at 9g/kg body weight daily for 3 consecutive months, and no toxic reaction was found. During the administration period, due to the increase in liver and kidney stress response under non-physiological conditions, it can be observed that the reticuloendothelial system, liver parenchyma and other tissues of the test animals have increased uptake and metabolism of hydroxyethyl starch. The minimum toxic dose of this product for daily intravenous infusion is higher than 9g/kg body weight, which is equivalent to more than 3 times the maximum therapeutic dose of humans. Studies conducted in rats or rabbits have shown that this product has no teratogenic toxicity. When rabbits were infused with 10% hydroxyethyl starch 130/0.4 solution 50ml/kg daily, embryonic death was observed. When pregnant and lactating rats were given a single bolus of the above dose, delayed weight gain and growth of the pups were observed, and increased fluid load was observed in the mother. No studies have been conducted on the effects of this product on fertility.

More

This product is a blood volume expander. Its volume expansion effect and blood dilution effect depend on the molecular weight, degree of substitution, substitution mode and drug concentration, as well as the dosage and infusion rate. After 500ml of this product was infused into healthy volunteers within 30 minutes, its volume expansion effect was 100% of the infusion volume of this product, and this 100% volume effect can be stably maintained for 4-6 hours. This product can maintain blood volume for at least 6 hours by isovolumetric blood replacement. In the subchronic toxicity test study of dogs and rats, this product was intravenously infused at 9g/kg body weight daily for 3 consecutive months, and no toxic reaction was found. During the administration period, due to the increase in liver and kidney stress response under non-physiological conditions, it can be observed that the reticuloendothelial system, liver parenchyma and other tissues of the test animals have increased uptake and metabolism of hydroxyethyl starch. The minimum toxic dose of this product for daily intravenous infusion is higher than 9g/kg body weight, which is equivalent to more than 3 times the maximum therapeutic dose of humans. Studies conducted in rats or rabbits have shown that this product has no teratogenic toxicity. When rabbits were infused with 10% hydroxyethyl starch 130/0.4 solution 50ml/kg daily, embryonic death was observed. When pregnant and lactating rats were given a single bolus of the above dose, delayed weight gain and growth of the pups were observed, and increased fluid load was observed in the mother. No studies have been conducted on the effects of this product on fertility.

7647-14-5 43
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.